AARD (Aardvark Pharma) Earnings growth in current year

AARD (Aardvark Pharma) - company brandmark

The key success factor for Aardvark Therapeutics Inc (AARD) is the progress in clinical trials of obesity treatments and the integrity of R&D data. The YoY change in net income per share illustrates the impact of liquidity on the stock value, where the -10.20 level captures the latest values. The company's prospects rely on the drug ARD-101, while business resilience is guaranteed by a product cycle that remains independent of macroeconomic conditions.

AARD: Aardvark Therapeutics Inc Earnings per share growth in current year 02/14/2025 - 11/18/2026

Financial and market metric breakdowns for Aardvark Therapeutics Inc. (AARD)

Basic company analysis:AARD - Aardvark Pharma
Finished products of Aardvark Therapeutics

This indicator measures the year-over-year dynamics of net earnings per share, reflecting capital generation efficiency and the growth rate of asset returns. For Aardvark Therapeutics Inc (AARD), which is developing innovative treatments for metabolic disorders, the history of annual earnings per share changes confirms market confidence in the business model, signaling high fundamental value and the quality of the company's assets.

Main competitors

ASND: Net earnings per one share growth for the current year|MDGL (Madrigal Corp) - Earnings growth in current year|Earnings growth in current year Corcept Therapeutics|Earnings growth in current year RYTM|Earnings per share growth in current year AKRO (Akero Therapeutics, Inc.)|Earnings per share growth in current year metsera.com MTSR|MoonLake Corp (MLTX) - Earnings per share growth rate in current year|CRNX - Earnings per share growth in current year|NAMS: Earnings per share growth in current year|SLNO: Earnings growth in current year|FOLD - Expected net earnings per share growth this year|Earnings per share growth in current year 89bio Pharma|Agios Corp (AGIO) - Expected net earnings per share growth this year|Earnings per share growth in current year structuretx.com (GPCR)|Net earnings per share growth this year mimedx.com MDXG|Earnings per share growth in current year Rezolute RZLT|Lexicon Pharmaceuticals, Inc. - Earnings per share growth in current year|MBX: Net earnings per share growth this year|Altimmune Corp - Net earnings per one share growth for the current year|SGMT: Earnings growth in current year|Earnings per share growth rate in current year BioAge Labs, Inc. (BIOA)|Earnings per share growth in current year Biomea Fusion Inc|Earnings per share growth this year QNCX (Quince Therapeutics)|Net earnings per share growth this year GUTS (Fractyl Health)|Net earnings per one share growth for the current year VTVT|Agape ATP Corporation - Net earnings per share growth this year|Earnings per share increase in current year PLUR|Synlogic Inc. - Earnings growth in current year|LPCN (Lipocine) - Earnings per share growth this year|MTNB (Matinas BioPharma Holdings Inc.) - Net earnings per share growth this year|SPRB (Spruce Biosciences, Inc.) - Earnings per share growth in current year|GLTO (galecto.com) - Earnings growth in current year|Net earnings per share growth this year carmellrx.com (CTCX)|Earnings per share growth in current year Lumos Pharma (LUMO)|ONVO (Organovo Holdings) - Earnings per share increase in current year|radiuspharm.com - Net earnings per share growth this year